Synchron, a U.S.-based developer of minimally invasive brain-computer interfaces, has raised $200 million in Series D financing, increasing its total funding to $345 million. The investment, led by Double Point Ventures with participation from ARCH Ventures, Khosla Ventures, Bezos Expeditions, and several new institutional backers, will help the company prepare its first-generation Stentrode system for commercial rollout.
The platform, placed through a catheter rather than open-brain surgery, enables patients with paralysis to convert neural activity into digital actions. It has been implanted in ten participants across U.S. and Australian studies, and Synchron has also collaborated with Apple to link its interface directly to iOS devices through a Bluetooth-enabled protocol. CEO Tom Oxley noted, “We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis.”
The company will use the new capital to accelerate pivotal trials, expand hiring and develop an advanced, higher-channel interface aimed at broader brain coverage. Its New York Cognitive AI division is training algorithms to interpret neural signals in real time, while its San Diego engineering hub builds next-generation hardware. Investors described the progress as a significant step toward accessible neurotechnology, with Double Point Ventures’ MD, Co-Founder and Managing Partner, Campbell Murray stating that “Synchron is building the first truly scalable, minimally invasive brain-computer interface that can be deployed in everyday healthcare.”
